Neurocrine announces phase II results of VMAT2 inhibitor INGREZZA® for Tourette syndrome
Neurocrine Biosciences announced the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA®(valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint. The pre-specified primary endpoint was the change-from-baseline between the placebo and active groups. May 23, 2017